Elisabet de los Pinos and her team fuel up for a late-stage quest to deliver a safe eye cancer drug

Since its founding in 2009, Aura Biosciences has been laser-focused on creating a safer alternative to currently available eye cancer therapies. And on Monday, the biotech pulled in $80 million to walk its lead candidate to Phase III.